Literature DB >> 17516614

Increased Fas and Bcl-2 expression on peripheral mononuclear cells from patients with active juvenile-onset systemic lupus erythematosus.

Bernadete Lourdes Liphaus1, Maria Helena Bittencourt Kiss, Solange Carrasco, Claudia Goldenstein-Schainberg.   

Abstract

OBJECTIVE: To determine expressions of Fas and Bcl-2 on peripheral blood T and B lymphocytes from patients with juvenile-onset systemic lupus erythematosus (JSLE).
METHODS: Thirty-eight patients with JSLE and 21 healthy controls were studied. Eleven JSLE patients with SLEDAI score >or= 8 were categorized as active. Freshly isolated peripheral blood mononuclear cells were stained for lymphocyte markers CD3, CD4, CD8, and CD19 and for Fas and Bcl-2 molecules. Cell protein expression was measured by 3-color flow cytometry.
RESULTS: Percentages of lymphocytes positively stained for Fas antigen and cytoplasmic expression of Bcl-2 measured by mean fluorescence intensity from patients were significantly increased compared to controls on CD3+, CD4+, and CD8+ T cells. Patients with active disease had higher percentages of CD19+ B cells positive for Fas antigen compared to patients with inactive lupus. A direct statistical correlation was observed between Fas and Bcl-2 expression on CD19+ B cells and SLE Disease Activity Index score.
CONCLUSION: Patients with juvenile-onset SLE show upregulation of apoptosis-related proteins. Patients with active and inactive disease have a different profile of Fas and Bcl-2 expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516614

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation.

Authors:  G L V de Oliveira; K C R Malmegrim; A F Ferreira; R Tognon; S Kashima; C E B Couri; D T Covas; J C Voltarelli; F A de Castro
Journal:  Clin Exp Immunol       Date:  2012-06       Impact factor: 4.330

2.  Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation.

Authors:  G L V de Oliveira; A F Ferreira; E P L Gasparotto; S Kashima; D T Covas; C T Guerreiro; D G Brum; A A Barreira; J C Voltarelli; B P Simões; M C Oliveira; F A de Castro; K C R Malmegrim
Journal:  Clin Exp Immunol       Date:  2016-12-23       Impact factor: 4.330

3.  Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Maria Helena B Kiss; Solange Carrasco; Patrícia Palmeira; Claudia Goldenstein-Schainberg; Magda Carneiro-Sampaio
Journal:  Clin Rheumatol       Date:  2017-04-04       Impact factor: 2.980

4.  Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.

Authors:  Ahmed Nader; Mukul Minocha; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

Review 5.  The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Maria Helena Bittencourt Kiss
Journal:  Clinics (Sao Paulo)       Date:  2010-03       Impact factor: 2.365

6.  Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma.

Authors:  Tomoyuki Tano; Masato Okamoto; Shin Kan; Koh-Ichi Nakashiro; Shigetaka Shimodaira; Shigeo Koido; Sadamu Homma; Mitsunobu Sato; Tomonobu Fujita; Yutaka Kawakami; Hiroyuki Hamakawa
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

Review 7.  Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies.

Authors:  Magda Carneiro-Sampaio; Bernadete Lourdes Liphaus; Adriana Almeida Jesus; Clovis Artur A Silva; João Bosco Oliveira; Maria Helena Kiss
Journal:  J Clin Immunol       Date:  2008-04-11       Impact factor: 8.317

8.  Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.

Authors:  Mukul Minocha; Jiewei Zeng; Jeroen K Medema; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

9.  Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus.

Authors:  Zhenpeng Dai; Cameron J Turtle; Garrett C Booth; Stanley R Riddell; Theodore A Gooley; Anne M Stevens; Thomas Spies; Veronika Groh
Journal:  J Exp Med       Date:  2009-03-16       Impact factor: 14.307

10.  Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Laila Lima; Patrícia Palmeira; Clóvis A Silva; Claudia Goldenstein-Schainberg; Magda Carneiro-Sampaio
Journal:  Clin Rheumatol       Date:  2019-10-26       Impact factor: 2.980

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.